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001), as well as significant improvements in progression-free survival (PFS), overall response rate, disease control rate, tumour-related symptoms and patient quality of life [4, 5]. In contrast, the pivotal phase III placebo-controlled study of gefitinib in previously treated advanced NSCLC patients, Iressa Survival Evaluation in Lung Cancer (ISEL), failed to demonstrate a statistically significant improvement in OS with gefitinib in the overall study population [6]. Second-line gefitinib was shown to be non-inferior to docetaxel in a multi-national study Iressa Non-Small-Cell Lung Cancer Trial Evaluating Response and Survival Against Taxotere (INTEREST) [7], but not in a similarly designed trial performed in Japanese patients (V15-32) [8]. A recent meta-analysis including data from INTER-EST, V15-32 and two other (open-label) studies of gefitinib versus docetaxel (second-line indication of gefitinib in NSCLC [SIGN] [9] and Iressa as Second-Line Therapy in Advanced NSCLC-Asia [ISTANA] [10]) concluded that the efficacy of gefitinib was similar to that of docetaxel in previously treated advanced NSCLC (hazard ratio [HR] for OS 1.03, 95% confidence interval [C.I.] 0.93-1.13) [11]. As two of the studies included in this meta-analysis were conducted exclusively in Asia, 43% of the 2257 patients were of Asian ethnicity. Biomarker analyses in the BR.21, ISEL, INTEREST and sequential Tarceva in UN resectable NSCLC (SATURN) studies [12-15] have indicated that patients with EGFR mutations have a pronounced response to EGFR TKIs; however, the relatively low rate of mutations and the limited availability of tumour samples from randomized trials make it difficult to conduct large-scale investigations of possible associations between EGFR mutations and therapeutic outcome. For this reason, we have performed an in-depth literature review to examine the evidence surrounding EGFRmutated NSCLC and have then conducted a pooled analysis of available studies to evaluate clinical outcome in patients with EGFR-mutated NSCLC, who have been treated with chemotherapy or EGFR TKIs.
Literature review
Molecular biology of EGFR mutations
EGFR is a 170-kDa member of the ErbB or human epidermal receptor (HER) family of tyrosine kinase (TK) growth factor receptors. Following binding of specific ligands, the transmembrane receptor homodimerizes with another EGFR protein or heterodimerizes with related proteins (primarily HER2/ErbB2). Once the dimer is formed, the intracellular enzymatic subunit of one EGFR phosphorylates several tyrosines of the other protein. This leads to the recruitment of additional intracellular signalling molecules, which begin a cascade that activates specific cellular growth and differentiation pathways [16]. EGFR has also been identified as a cellular proto-oncogene with close sequence homology to the viral oncogene v-erb-B [17] and is expressed in a variety
Genetic characteristics of EGFR-mutated tumours
Prognostic significance of NSCLC with EGFR mutations
Methods
Selection criteria
All prospective or retrospective studies were eligible for the study pool if they evaluated chemotherapy or single-agent EGFR TKIs (erlotinib or gefitinib) in patients with NSCLC and EGFR mutations. Among the studies identified for inclusion, a variety of techniques were used to determine the EGFR mutation status of tumours; the methods used in individual reports were not critically assessed as part of this analysis.
Search strategy
The medical literature was reviewed to identify appropriate clinical studies for pooled analysis inclusion. The Datastar Web search engine was used to search Medline, Biosis previews and Embase (excluding reviews, and non-English language) on June 11, 2009 using the search string ('epidermal growth factor' OR EGFR) AND (lung OR NSCLC) AND (mutation OR mutations). Searches were limited to studies published in 2004 or later (given that EGFR TK domain mutations were first identified in NSCLC in 2004
. In the weighted, pooled analysis, shown in Fig. 4 
Publication bias
Potential publication bias was assessed using funnel plots with PFS or TTP as the outcome. The funnel plots were symmetrical for each of the treatment groups (Fig. 5A-C 
